Harmony Biosciences Holdings, Inc. Sustainability Profile
Harmony Biosciences Holdings, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with rare neurological disorders. Founded in 2017, the company has quickly established itself in the industry, particularly in the field of sleep medicine and central nervous system disorders. With a commitment to addressing unmet medical needs, Harmony Biosciences offers unique products such as WAKIX® (pitolisant), which is designed to treat narcolepsy. This medication stands out due to its novel mechanism of action, providing patients with effective symptom management. The company has achieved significant milestones, including rapid growth and recognition for its contributions to improving patient outcomes in the neurology sector. Harmony Biosciences continues to strengthen its market position through ongoing research and development, aiming to expand its portfolio and enhance the lives of those affected by rare diseases.
DitchCarbon Score
How does Harmony Biosciences Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harmony Biosciences Holdings, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harmony Biosciences Holdings, Inc.'s reported carbon emissions
Harmony Biosciences Holdings, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As there are no emissions data or reduction initiatives available, it is unclear how Harmony Biosciences aligns with industry standards for climate action. The absence of specific targets or commitments may reflect a broader trend within the pharmaceutical sector, where companies are increasingly being called upon to disclose their environmental impact and set ambitious sustainability goals. In summary, without available emissions data or reduction initiatives, Harmony Biosciences Holdings, Inc. currently lacks a defined strategy for addressing carbon emissions and climate commitments.
How Carbon Intensive is Harmony Biosciences Holdings, Inc.'s Industry?
How Carbon Intensive is Harmony Biosciences Holdings, Inc.'s Location?
Harmony Biosciences Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Harmony Biosciences Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
